Advertisement Lantheus acquires US, Canadian, and Australian rights to Epix's MRA agent - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More

Lantheus acquires US, Canadian, and Australian rights to Epix’s MRA agent

Lantheus Medical Imaging, a provider of diagnostic imaging, has acquired from Epix Pharmaceuticals, the US, Canadian, and Australian rights to MS-325, a novel magnetic resonance angiography or MRA agent.

Under the terms of the agreement, Lantheus acquired the US, including Puerto Rico, Canadian, and Australian rights to MS-325 from Epix. Epix will continue to own European and other ex-US rights for the imaging agent. Lantheus is planning to launch MS-325 under a different name before the year-end of 2009.

In December 2008, Epix received FDA marketing approval for MS-325 to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease. Currently, there are no other imaging agents approved for magnetic resonance angiography in the US.

The acquisition of MS-325 is expected to further Lantheus’s diagnostic imaging product portfolio and expand the company’s presence to the radiology market.

Don Kiepert, president and CEO of Lantheus Medical Imaging, said: “The acquisition of MS-325 reinforces our growth strategy to continue to bring to market breakthrough new imaging tools. We are pleased with this important acquisition and look forward to making this diagnostic tool available to physicians to improve diagnosis and patient management.”